Clinical Trial Search

Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants

Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants

Primary: Clinical Tumor Regression — 1 Participants

Primary: Part 2: Median Progression-free Survival (PFS) in Weeks Based on Enhanced Response Evaluation Criteria In Solid Tumors Version 1.1 (Enhanced RECIST 1.1) by Independent…

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Incidence of Dose-limiting Toxicities (DLTs) Defined as the Rate of Drug-related Grade 3-5 Adverse Events Assessed Using the National Cancer Institute Common Terminology…

Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants

Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Number of Participants Who Experienced Toxicity to the Vaccine — 0; 0 Participants

Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…

Primary: Best Overall Response — 0; 0; 13; 11 participants

Primary: Number of Participants With Treatment-Emergent Adverse Events — 2; 0 Participants

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: PFS — 29.8 Months

Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants

Primary: Tumor Response — 1; 9; 17; 18 participants

Primary: To Evaluate Progression-free Survival of Paclitaxel/Carboplatin and Pembrolizumab in Patients With Advanced Stage, Metastatic Ovarian Cancer Undergoing NACT — 14.2 months

Primary: Overall Objective Response — 10; 13; 11; 4 participants

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events — 1; 9; 20; 9 Participants

Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants

Primary: Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or…

Primary: Progression-free Survival — 25 months

Primary: Overall Response Rate — .083 proportion of participants

Primary: Overall Survival — 32 months

Primary: Objective Tumor Response — 12.5; 12.1 percentage of participants